These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23061703)

  • 1. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
    Altan E; Masaoka T; Farré R; Tack J
    Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.
    Tack J; Janssen P
    Expert Opin Investig Drugs; 2011 May; 20(5):701-12. PubMed ID: 21417958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.
    Suzuki H; Hibi T
    Neurogastroenterol Motil; 2010 Jun; 22(6):595-9. PubMed ID: 20553562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration.
    Matsueda K; Hongo M; Ushijima S; Akiho H
    Digestion; 2011; 84(4):261-8. PubMed ID: 21934307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
    Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.
    Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J
    Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
    Matsueda K; Hongo M; Tack J; Aoki H; Saito Y; Kato H
    Neurogastroenterol Motil; 2010 Jun; 22(6):618-e173. PubMed ID: 20059698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
    Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K
    Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of acotiamide for the treatment of functional dyspepsia.
    Sun Y; Song G; McCallum RW
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1161-8. PubMed ID: 24881488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
    Tack J; Masclee A; Heading R; Berstad A; Piessevaux H; Popiela T; Vandenberghe A; Kato H
    Neurogastroenterol Motil; 2009 Mar; 21(3):272-80. PubMed ID: 19254354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
    Matsushita M; Masaoka T; Suzuki H
    Neurogastroenterol Motil; 2016 May; 28(5):631-8. PubMed ID: 26730749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kawarai Lefor A; Yamamoto H
    J Med Invest; 2016; 63(3-4):230-5. PubMed ID: 27644564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World, Non-Interventional, Observational Study to Evaluate Effectiveness and Tolerability of Acotiamide Hydrochloride Hydrate in Treatment of Functional Dyspepsia.
    Porika SK; Veligandla KC; Muni SK; Acharya S; Mehta SC; Sharma AD
    Adv Ther; 2018 Nov; 35(11):1884-1893. PubMed ID: 30350248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
    Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
    Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging therapeutic options for the management of functional dyspepsia.
    Vandenberghe A; Schol J; Van den Houte K; Masuy I; Carbone F; Tack J
    Expert Opin Pharmacother; 2020 Feb; 21(3):365-376. PubMed ID: 31899982
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of Acotiamide Versus Mosapride in Patients With Functional Dyspepsia Associated With Meal-Induced Postprandial Distress Syndrome: A Phase III Randomized Clinical Trial.
    Sinha S; Chary S; Thakur P; Talluri L; Reddy M; K GS; Mohan JM; Jain P; Naik S; C Reddy SV
    Cureus; 2021 Sep; 13(9):e18109. PubMed ID: 34692320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
    Matsueda K; Hongo M; Tack J; Saito Y; Kato H
    Gut; 2012 Jun; 61(6):821-8. PubMed ID: 22157329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.
    Futagami S; Shimpuku M; Song JM; Kodaka Y; Yamawaki H; Nagoya H; Shindo T; Kawagoe T; Horie A; Gudis K; Iwakiri K; Sakamoto C
    Digestion; 2012; 86(2):114-21. PubMed ID: 22846371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria.
    Vanheel H; Carbone F; Valvekens L; Simren M; Tornblom H; Vanuytsel T; Van Oudenhove L; Tack J
    Am J Gastroenterol; 2017 Jan; 112(1):132-140. PubMed ID: 27958284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rome III functional dyspepsia subdivision in PDS and EPS: recognizing postprandial symptoms reduces overlap.
    Carbone F; Holvoet L; Tack J
    Neurogastroenterol Motil; 2015 Aug; 27(8):1069-74. PubMed ID: 26220647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.